Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-bridge Cycle01:26

Cross-bridge Cycle

121.7K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
121.7K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.6K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.6K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.6K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.8K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An induced pluripotent stem cell-based chemical genetic approach for studying spinal muscular atrophy.

Frontiers in neuroscience·2026
Same author

Liver Steatosis in Induced Hepatocytes From Carriers of Spinal Muscular Atrophy.

Muscle & nerve·2026
Same author

An induced pluripotent stem cell-based chemical genetic approach for studying spinal muscular atrophy.

bioRxiv : the preprint server for biology·2025
Same author

Activated GDF11/8 subforms predict cardiovascular events and mortality in humans.

Nature communications·2025
Same author

Combinatory Treatment to Alleviate Cellular Stress and Improve Skeletal Muscle Phenotype in Spinal Muscular Atrophy.

Circulation research·2025
Same author

Potential of synergist ablation to study mechanisms of skeletal muscle hypertrophy in rodent disease models.

American journal of physiology. Cell physiology·2025

Related Experiment Video

Updated: Dec 25, 2025

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.5K

Spinal Muscular Atrophy: Huge Steps.

Kelly Howell, Rebecca M Gibbs, Lee L Rubin

    Cerebrum : the Dana Forum on Brain Science
    |March 25, 2020
    PubMed
    Summary
    This summary is machine-generated.

    Spinal muscular atrophy (SMA) is a leading genetic cause of infant mortality. Recent therapeutic advancements have significantly improved survival rates for infants diagnosed with SMA.

    More Related Videos

    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
    06:35

    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

    Published on: June 15, 2018

    20.3K
    Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis
    06:12

    Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

    Published on: January 11, 2014

    12.2K

    Related Experiment Videos

    Last Updated: Dec 25, 2025

    Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
    12:35

    Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

    Published on: March 17, 2012

    28.5K
    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
    06:35

    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

    Published on: June 15, 2018

    20.3K
    Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis
    06:12

    Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

    Published on: January 11, 2014

    12.2K

    Area of Science:

    • Neurology
    • Genetics
    • Pediatrics

    Background:

    • Spinal muscular atrophy (SMA) is the primary genetic cause of death in infants.
    • Historically, infants with SMA faced a grim prognosis, with over 50% succumbing before age two due to progressive muscle weakness affecting vital functions.
    • While medical care has offered some improvement, recent breakthroughs are transforming outcomes.

    Purpose of the Study:

    • To review the current landscape of spinal muscular atrophy.
    • To highlight recent therapeutic developments and their impact on survival rates.
    • To discuss the future outlook for managing SMA.

    Main Methods:

    • Review of recent scientific literature on spinal muscular atrophy.
    • Analysis of survival data in relation to medical interventions and new therapies.
    • Synthesis of information on ongoing research and potential future treatments.

    Main Results:

    • Significant improvements in survival rates for infants with SMA have been observed.
    • New therapeutic strategies are demonstrating considerable efficacy.
    • The outlook for infants diagnosed with SMA is becoming increasingly positive.

    Conclusions:

    • Advances in understanding and treating SMA have dramatically improved patient outcomes.
    • Continued research and development promise further enhancements in care and survival for individuals with SMA.
    • The trajectory for managing SMA has shifted from palliative care to potentially life-altering treatment.